Article
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
The lancet. Gastroenterology & hepatology - 1 Sept 2020
Wei Lai, Wang Guiqiang, Alami Negar N, Xie Wen, Heo Jeong, Xie Qing, Zhang Mingxiang, Kim Yoon Jun, Lim Seng Gee, Fredrick Linda M, Lu Wenjing, Liu Wei, Kalluri Hari V, Krishnan Preethi, Tripathi Rakesh, Mobashery Niloufar, Burroughs Margaret, Asatryan Armen, Jia Jidong, Hou Jinlin
Abstract excerpt
BACKGROUND: Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been minimal. The aim of these studies was to assess the efficacy and safety of glecaprevir-pibrentasvir in treatment-naive and treatment-experienced Asian patients with chronic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.